What is Bioniq?
Bioniq operates at the intersection of health technology and artificial intelligence, offering personalized supplements derived from blood test data. The company leverages advanced analytics to tailor nutritional recommendations, positioning itself as an industry leader in the burgeoning field of personalized wellness. Its innovative approach aims to optimize individual health outcomes through data-driven insights.
How much funding has Bioniq raised?
Bioniq has raised a total of $22.8M across 2 funding rounds:
Series A
$7.8M
Series B
$15M
Series A (2021): $7.8M with participation from OKS Group incorporated
Series B (2024): $15M led by Unbound and HV Capital
Key Investors in Bioniq
Unbound
Unbound is an investor participating in the funding round, likely focused on innovative health and wellness ventures.
HV Capital
HV Capital is a venture funding firm that invests in companies in the early stages of business, with a focus on technology and innovation.
OKS Group incorporated
OKS Group incorporated is an investor that participated in Bioniq's Series A funding, indicating a prior strategic interest in the company's development.
What's next for Bioniq?
The recent major enterprise-level funding signals Bioniq's readiness for significant scaling and market expansion. This strategic investment is likely to fuel further research and development into its AI algorithms, enhance its product offerings, and broaden its customer reach. The company is poised to solidify its leadership in the personalized nutrition sector, potentially exploring new markets and strategic partnerships to accelerate its growth.
See full Bioniq company page
